Weight loss drug opportunity is increasingly coming into focus for Indian pharma
Weight loss drugs, which took the US market by storm, are looking to be a big opportunity for drug makers in India. Several ...
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
Nation-wide Ozempic shortage impacting people with diabetes especially in regional Australia
Experts are calling on the government to implement strategies that will better predict future Ozempic shortages.
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharma Industries Ltd ADR, Allergan PLC, Johnson & Johnson, CVS Health Corp. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...
Monthly Prescribing Reference2d
Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease
The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...